Summary:
Lucid Diagnostics and Hoag have launched a comprehensive esophageal precancer screening program using the non-endoscopic EsoGuard DNA test to enhance early detection and prevention of esophageal cancer.

Takeaways:

  • Hoag will integrate EsoGuard testing across its digestive health, primary care, and concierge medicine programs.
  • The goal is to identify at-risk patients early using a quick, non-invasive 3-minute test.
  • This partnership marks a key step in expanding EsoGuard’s availability through large healthcare systems.

Lucid Diagnostics Inc., a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc., has announced that Hoag, a nationally-recognized regional healthcare delivery network, has launched a comprehensive, integrated esophageal precancer testing program using Lucid Diagnostics’ EsoGuard Esophageal DNA Test. Lucid will partner with Hoag to offer EsoGuard testing across its digestive health, primary care, and concierge medicine programs.

“This is a game changer in our mission towards achieving an esophageal cancer-free Orange County,” says Kenneth J. Chang, MD, the James & Pamela Muzzy executive medical director endowed chair in GI Cancer at Hoag’s Digestive Health Institute. “The incidence of esophageal cancer has increased tenfold in the past four decades, yet most patients at risk are not being identified. Adding EsoGuard to our comprehensive esophageal cancer screening program here in Orange County is a critical step in finding patients who may be at risk, using a 3-minute non-endoscopic test, with the ultimate goal of saving lives.”

“We are thrilled to partner with a renowned, world-class healthcare system like Hoag,” says Lishan Aklog, MD, Lucid’s chairman and chief executive officer. “It’s always great to find partners such as Dr. Chang and his colleagues who share our mission to eliminate the scourge of esophageal cancer. This partnership also represents an important milestone in expanding access to EsoGuard within large healthcare systems, and we expect our collaboration with Hoag will serve as a model for additional leading health systems to offer EsoGuard testing across their healthcare delivery networks.” 

Featured Image: Skypixel | Dreamstime.com